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Podocalyxin (PODXL) is a type I membrane sialomucin, originally described in 
the epithelial cells (podocytes) of kidney glomeruli. PODXL is also found in 
extra-renal tissues and in certain aggressive tumors, but its precise 
pathophysiological role is unknown. Expression of PODXL in CHO cells 
enhances their adhesive, migratory and cell-cell interactive properties in a 
selectin and integrin-dependent manner. We aimed at defining the PODXL 
domains responsible for those cell responses. For this purpose we have 
analyzed the cell adhesion/migration responses to deletion mutants of human 
PODXL, and the correlation with the activities of Rac1 and Cdc42 GTPases. 
The results obtained indicate that integrity of the PODXL ectodomain is 
essential for enhancing cell adhesion but not migration, while the integrity of the 
cytoplasmic domain is required for both adhesion and migration. Deletion of the 
carboxy-terminal DTHL domain (PODXL-!DTHL) limited only cell adhesion. The 
activities of Rac1 and Cdc42 GTPases parallel the PODXL-induced variations in 
cell adhesion and migration. Moreover, silencing the rac1 gene virtually 
abolished the effect of PODXL in enhancing cell adhesion. 
 







Podocalyxin (PODXL) is a type I membrane protein of the CD34 family 
originally described at the luminal side of the epithelial cells of renal glomeruli 
(podocytes) [1]. The PODXL peptide has a molecular mass of 45 KDa that after 
extensive posttranslational processing results in a highly sulfated and sialylated 
[2,3] mature protein of 140 to 200 KDa [4,5]. A loss of the structural 
organization of the podocytes, “effacement”, [6,7] and PODXL excretion in the 
urine are considered markers for the detection and/or progression of kidney 
inflammatory diseases [8,9]. PODXL appears in the glomerular podocytes at the 
same time as the opening of the intercellular spaces [10] and disappearance of 
the tight junctions [11]. PODXL-null mice die of anuria a few hours after birth 
[12]. Based on these observations, the proposal has been made that PODXL 
would act as an anti-adhesive force in the kidney glomeruli [13], contributing to 
maintain open the podocyte interdigitations, “urinary slits” [3].   
PODXL has also been found in vascular endothelium, lung, brain, multipotent 
hematopoietic precursors, megakaryocytes and platelets [4,14,15], as well as in 
several types of tumors in which the expression levels appear to correlate with 
the metastatic capacity [16,17,18]. However, unlike the role of PODXL in the 
renal homeostasis, almost nothing is known about its physiological role in extra-
renal tissues. We have previously reported that expression of human PODXL in 
CHO cells enhances their adhesion, migration and cellular interaction [19,20]. 
Moreover, the restricted ablation of the podxl gene in megakaryocytes added 
further evidence in support of PODXL as a proadhesive molecule [21]. In high 
endothelial venules (HEV), PODXL binds L-selectin from circulating leucocytes 
and interact with integrins [22]. In contrast with CHO cells, PODXL has been 
reported to confer cell anti-adhesive properties to canine kidney and other cells 
[23,24,25,26]. How PODXL could exert either pro-adhesive or anti-adhesive 
effects, is a subject of debate. It should be noted that the function of PODXL 
could be influenced by the presence of extracellular soluble sPODXL [27]. 
 
The present work aimed at analyzing the functional properties of CHO cells 
stably expressing amino- or carboxy-terminal deletion mutants of PODXL and 
the correlation with the activities of the actin cytoskeletal organizers Rac1 and 
! %!
Cdc42 GTPases. The results indicate that integrity of the PODXL ectodomain is 
essential for enhancing cell adhesion but not cell migration. The state of 
activation of Rac1 and Cdc42 parallels the PODXL-induced variations in 
adhesion and migration. Moreover, silencing the rac1 gene prevented the 
effects of PODXL. Deletion of the entire cytosolic tail of PODXL (PODXL-!452) 
virtually abolished the enhancing effects on cell adhesion and migration. 
Deletion of the last four carboxy-terminal residues (Aspartate-Threonine-
Histidine-Leucine) (PODXL-!DTHL) restricted cell adhesion, but not migration. 
The activation of Rac1 and Cdc42 induced by PODXL was fully prevented by 
deletion of the cytosolic tail (PODXL-!452) and diminished by deletion of the 
DTHL domain (PODXL-!DTHL). 
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2. Material and methods 
2.1. Materials 
The antibodies used were: mouse anti-podocalyxin (3D3), goat anti-cytosolic 
domain of podocalyxin (K19), rabbit polyclonal anti-NHERF-1 (H-100), and anti-
GFP (FL), mouse monoclonal anti-ezrin (3C2), anti-cortactin (F-9), and normal 
mouse IgG-AC (negative control for immunoprecipitation), all of them obtained 
from Santa Cruz Biotechnology. The endonuclease prepared siRNA, targeting 
mouse Rac1 was obtained from Sigma Aldrich. 
 
2.2. Cell lines and culture conditions 
The cell lines stably expressing GFP, PODXL bearing a GFP tag either at the 
carboxy terminus (PODXL-GFP) or the amino-terminus (GFP-PODXL), or 
PODXL deletion mutants, prepared as previously described [19,20,27], were 
grown in DMEM-HT medium (Gibco) supplemented with 10% bovine fetal 
serum, 100 U/mL penicillin-G (Gibco) and 250 µg/mL streptomycin (Gibco), at 
37ºC and 5% CO2.  
 
2.3. Western blotting and immunoprecipitation.  
Cell lysates from the different cell lines were prepared in modified RIPA buffer 
(50 mM pH 7.4 Tris-HCl, 1% NP-40, 0.25% Na-deoxycholate, 150 mM NaCl) 
supplemented with 1 mM PMSF, 1 mM Na3PO4, 1 mM NaF and a protease 
inhibitor cocktail (Roche, Indianapolis, IN), and loaded into 7.5 % SDS-
polyacrylamide gels under reducing conditions. Proteins were transferred to 
nitrocellulose membranes and visualized after overnight incubation with anti-
PODXL or anti-GFP moAbs at 4ºC temperature, followed by HRP-conjugated 
secondary goat anti-mouse IgG. Blots were developed using an enhanced 
chemiluminescence’s detection system (ECL). The immunoprecipitation 
experiments were performed using Protein-G Sepharose beads (Pharmacia).  
 
2.4. Preparation of PODXL mutants. 
To prepare PODXL deletion mutants with the signal peptide, we first prepared 
an expression vector coding a fusion protein containing the PODXL signal 
peptide and GFP. For this purpose the signal peptide sequence was amplified 
by PCR from the expression vector human PODXL cDNA-pcDNA3 [19,20], 
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using oligonucleotides 977-1007-Kozak ATG (5’-CCC CGC GGC GAC GCC 
ACC ATG GGC TGC GCG-3’) and 1109-1079 (5’-CGG CGA GGA TCC CGA 
CGG CAG CAG CGG CGG-3’), containing restriction sites SacII and BamHI, 
respectively. The PCR product was cloned in the pCR 2.1-TOPO vector, and a 
178-bp fragment containing the PODXL signal peptide was obtained by 
digestion with Hind III and Xba I, purified and, then, digested with SacII and 
BamH1, and cloned in the pEGFP-N1 vector (PS-PODXL-GFP vector).  
In a second step, cDNA fragments corresponding to each deletion mutants 
were obtained by PCR and cloned into the pcDNA3 vector. For deletion 
mutants of the ectodomain ("49-PODXL, "151-PODXL and "428-PODXL), 
sense oligonucleotides 5’-TCT AAC AAA ACA GGA TCC ACT CCA GCA-3’, 5’-
ACA GCT AAA CCT GGA TCC ACA AGC AGC CAG-3’ and 5’-CGC TTC AGC 
GGA TCC CTC ATC ATC ACC ATC-3’, respectively, and a common antisense 
oligonucleotide 1846-1822: 5’-CAG AGG ATC CAA GAG GTG TGT GTC-3’, all 
of them containing a BamH I site, were used. 
The PCR products were digested with BamH I, purified and cloned in the PS-
PODXL-GFP vector prepared in the first step of the procedure.  
For deletion mutants of the cytoplasmic domain (PODXL-!DTHL and PODXL-
!452), the sense oligonucleotide 977-1007-Kozak ATG, and antisense 
oligonucleotides 5’-CTA GAG GTG TGT GGA TCC CTC CTC ATC CAG-3’ and 
5’-GGA GAG GCG GGA TCC GCA GCA GCC ATA GAG-3’, containing BamH I 
sites, were used. The PCR products were digested with SacII/BamH I and 
cloned in the pEGFP-N1 vector. All the constructs were verified by DNA 
sequencing. 
 
2.5. Stable transfection of PODXL deletion mutants. 
CHO cells were transfected with the calcium phosphate technique and cells 
expressing PODXL were selected using G-418 and purified by subsequent 
rounds of cell sorting. The degree of expression of the different constructs was 
verified by flow cytometry and Western blot using anti-PODXL and anti-GFP 
Abs (Fig. 1).  
 
2.6. Cell adhesion assay. 
Cell adhesion experiments were carried out as previously described [20]. 
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Briefly, 96-well flat-bottomed plates were coated with 10 µg/mL fibronectin in 
PBS for 2 h at 37°C and blocked with 200 µL of 1% bovine serum albumin 
(BSA). CHO cells growing in DMEM containing 10% fetal bovine serum were 
starved for 24 h, harvested by EDTA treatment, collected by centrifugation and 
suspended in serum-free DMEM with 0.1% BSA and 0.1% glucose. Then, 100 
µL of 75x103 cells/well were plated in triplicate and incubated for the indicated 
periods of time at 37°C. Non-adherent cells were removed by careful washes 
with PBS and the degree of adherence and spreading analyzed at a 
magnification of 10x with a phase-contrast Olympus microscope IX-50, 
micrographs taken with a digital camera Olympus DP-70 and the number of 
adhered cells blind counted. 
 
2.7. Wound healing assay. 
The directional migration of cells expressing PODXL-GFP and the deletion 
mutants was determined by a “wound healing” assay. Cells (2x106) were 
seeded in DMEM medium with 10% FCS in 6-well fibronectin-coated culture 
plates. Once the cells adhered and spread, a scrape wound was created with a 
P10 pipette tip pushed perpendicularly through the monolayer. The plates were 
washed twice with PBS, incubated in full medium, and photographed 
immediately (0 h). After different times of incubation the migration of cells 
across the wound was evaluated by phase contrast microscopy. Cell migration 
was quantified by measuring the distance between the wound edges before and 
after migration at distinct positions, and the results were expressed as the % of 
wound closure. 
 
2.8. Rac1 and Cdc42 activation and silencing of Rac1. 
The activation of Rac1 and Cdc42 in cell lysates was performed with the Rac1 
activation assay kit from Millipore. To silence Rac1 we used either 6 or 24 pmol 
of siRNA targeting Rac1 (Sigma Mission esiRNA) for 12-well plates or 60 mm 
plates, respectively, using the Mission non-target shRNA control vector as 
negative control. The siRNA was transfected with Turbofect siRNA reagent 
(Fermentas) according to the protocol of the manufacturer for adherent cells. 
 
3. Results and discussion 
! )!
The deletions of PODXL generated for this study, represented in the scheme of 
Fig. 1, were as follows. The signal peptide (residues 1-22) was included in all 
constructs. !49-PODXL: Deletes residues 23 to 49, both included, eliminating 
two potential N-glycosylation sites (residues 33 and 43). !151-PODXL: Deletes 
residues 23 to 151, both included. This mutant lacks four potential N-
glycosylation sites (residues 33, 43, 104 y 144) and two potential glucose-
aminoglycan binding sites (102-104 and 115-117). !428-PODXL: Deletion of 
residues 23 to 428, both included, losing five potential N-glycosylation sites 
(residues 33, 43, 104, 144 and 322), four potential glucose-aminoglycan binding 
sites (102-104, 115-117, 160-162 and 206-208) and four cysteines (aa 314, 
337, 351 and 367) postulated to form disulfide bridges [5]. PODXL-!452: The 
cytosolic tail was deleted from residue 452.  PODXL-!DTHL: This mutation 
removes the last four carboxy-terminal residues Aspartate-Threonine-Histidine-
Leucine (DTHL).  
The levels of expression of the different mutant forms of PODXL were assessed 
by Western blot of cell lysates (Fig. 1B). PODXL-GFP expressed in CHO cells 
co-immunoprecipitates with ezrin and NHERF-1 [23,28] (Fig. 2A) indicating a 
similar function than the native PODXL expressed in kidney cells. In agreement 
with a previous report [29], PODXL in CHO cells has also been reported to 
interact with cortactin, as it was detected in anti-cortactin immunoprecipitates 
(Fig. 1C, lower right panel). We have also found cortactin in anti-PODXL 
immunoprecipitates (Fig. 1C lower left panel).  
Fig. 2A represents the number of cells expressing either PODXL-GFP or 
PODXL-mutants adhered onto fibronectin-coated plates. In agreement with 
previous reports [19,20], PODXL enhanced the basal rate of adhesion of cells 
by 40-50%. Deletion of the first 49 amino terminal residues of PODXL (!49-
PODXL) further enhanced the adhesion of cells, but the stimulating effect on 
cell adhesion decreased progressively as the length of the deleted fragment 
increased up to 151 or 428 residues (!151-PODXL and !428-PODXL, 
respectively.  
We further analyzed the effect of PODXL deletion mutants on cell migration by 
the “wound-healing assay” (Fig. 2B). As with cell adhesion, CHO-!49-PODXL 
cells migrated even faster than cells expressing intact PODXL, but this effect 
disappeared in cells expressing either !151-PODXL or !428-PODXL, that 
!
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showed similar rates of migration than CHO-PODXL cells, indicating that 
integrity of the ectodomain is not essential for PODXL to enhance cell 
migration. Dissociation of the PODXL effects on cell adhesion and migration 
has been previously observed by Hsu et al. in kidney cells [23]. These data 
suggest that interaction of the surface exposed PODXL with external agents is 
essential to either generate or transmit outside-in signaling controlling cell 
adherence. These data agrees with previous work in which deficiently sialylated 
CHO-PODXL cells failed to enhance cell adhesion [20]. 
Deletion of the entire cytosolic tail of PODXL (PODXL-!452) virtually abolished 
the PODXL effect on adhesion, whereas deletion of the carboxy-terminal DTHL 
domain (PODXL-!DTHL) reduced the PODXL effect (Fig. 2A). The observation 
that the terminal DTHL domain is needed for the PODXL effect on adhesion 
implies that it is operative despite bearing the the carboxy-terminus GFP tag. 
Moreover, as previously reported [27] no detectable differences in enhancing 
cell adhesion could be found when the GFP tag was linked to the amino-
terminus of PODXL, (GFP-PODXL) (Fig. S1). These observations suggest that 
signaling pathways other than those mediated by the interaction of the DTHL 
domain with NHERF-1 and ERM complex must be mediating the PODXL action 
on cell migration. Cortactin could a candidate for this interaction, that regulates 
cell motility through binding to Arp 2/3 [30], and reacts with PODXL [29]. In fact, 
we found cortactin in PODXL immunoprecipitates from CHO-PODXL cell 
lysates (Fig. 1). Since ezrin may interact with PODXL not involving the DTHL 
domain [31], perhaps it should also be considered as a potential factor involved 
in controlling the PODXL action.  
The participation of NHERF proteins and ERM complex in the action of PODXL 
implies the involvement of cytoskeletal organizers Rac1 and Cdc42, members 
of the Rho family of small GTPases [23]. Thus, we studied the activities of Rac1 
and Cdc42 in cells transfected with the different PODXL mutants. Expression of 
PODXL-GFP was accompanied by activation of both Rac1 and Cdc42 above 
the control values (CHO-GFP) (Fig. 3). The !49-PODXL mutant, that showed a 
marked effect in enhancing cell adhesion and migration (Fig. 2), did also show a 
significant increase in the Rac1 and Cdc42 activities. To note, the enhancing 
functional effects of removing the amino-terminus PODXL is consonant with the 
positive association of variants of PODXL carrying in-frame deletions of 2, 4 or 
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6 amino acids at positions 23-24, 23-26 or 23-28, respectively, with the risk of 
both prostate cancer and tumor aggressiveness [18]. 
The !151-PODXL and !428-PODXL mutants produced an activation of 
GTPases, although to a much lesser extent than PODXL-GFP or !49-PODXL.  
PODXL-!452 and PODXL-!DTHL produced changes in Rac1 and Cdc42 
activation parallel to the variations on cell adhesion and migration. To note, 
PODXL-!DTHL produced a significant activation of Rac1 and Cdc42, although 
the activation was smaller than that produced by intact PODXL.  
To assess the participation of Rac1 in the enhancing effects of PODXL on cell 
adhesion and migration, we knocked down the rac gene by transfecting Rac1-
iRNA. The time course of Rac1 knockdown is shown in Figs. 4A-B. The 
maximum effect of iRNA was obtained at 48 h and partially reversed at 72 h. 
The enhancing effects of PODXL in cell adhesion and migration were prevented 
24 h after the administration of Rac1-iRNA (Fig. 4C). The effect of PODXL on 
cell adhesion parallels Rac1 knockdown, recovering after 72 h (Fig. 4B). Similar 
observations were obtained by using other PODXL deletion mutants. 
The dependence of PODXL action on integrins [20] agrees with the postulate 
that activation of GTPases would contribute to integrin clustering and 
positioning within the cell adhesion contacts. However, the present work does 
not explain how PODXL could enhance the proposed integrin-mediated 
activation of small GTPases. Whatever the signaling mechanism, the lack of 
effects of PODXL in the absence of its cytosolic tail implies a participation of the 
intracellular tail of PODXL in the signaling path. 
The present results seem to be in conflict with the postulated anti-adherent 
properties of PODXL in renal podocytes [32]. The close relationship between 
the PODXL effect in enhancing cell adhesion and the activity of the small 
GTPases rules out any possible artifact in the PODXL effects. Moreover, 
silencing the rac1 gene abolished the PODXL effect in enhancing cell 
adhesion/migration. A differential distribution of intracellular regulatory proteins 
[24] could be of importance to explain the distinct effects of PODXL in different 
experimental models. 
To summarize, the use of deletion mutants suggest that a domain 
encompassed by residues 49 to #151 determines the enhancing effect of 
PODXL on cell adhesion, suggesting the operation of an outside-in signal. In 
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contrast, cell migration could be detected even in the absence of the entire 
ectodomain, suggesting that interaction of the intracellular domain of PODXL 
with intracellular regulatory proteins suffices to enhance cell migration. The 
finding of parallel changes in cell adhesion/migration and Rac1 and Cdc42 
activities and the effect of rac1 suppression on the PODXL effects, suggests 
that reorganization of the cytoskeletal network mediated by GTPases plays a 
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FIGURE 1. Characterization of PODXL deletion mutants. A) Scheme of 
PODXLGFP and location of deletion. Abbreviations: SP, signal peptide; EC, 
ectodomain; C4, cysteine domain; TMD, transmembrane domain; CD, cytosolic 
domain; GFP, green flurorescence protein; B) Western blot identification of 
PODXLGFP and its ectodomain (left panel) and cytosolic domain (right panel) 
deletion mutants. The experiment was performed using the indicated antibodies 
as described in Methods. C) Co-precipitation of PODXL-GFP with ezrin, 
NHERF-1 or cortactin in CHO cells. The experimental procedures are described 
in Methods. IPP, stands for immunoprecipitation antibody or immunoprecipitate; 
L, lysate; WB, Western blot detection antibody, iAb, mouse negative control for 
immunoprecipitation.  
 
FIGURE 2. Adhesion and migration of CHO cells, expressing PODXL-GFP or 
its deletion mutants, onto fibronectin-coated plates. A) Cell adhesion. The 
results are average values of three different experiments performed in 
duplicate, as described in Methods, at 20 min after cell seeding. The values 
represent the percentage of increase over the CHO-GFP cells. B) Cell migration 
determined by the wound-healing assay as described in Methods. The results 
are average values of three different experiments at 12 h after seeding. By 
paired t test: * P< 0.05 versus CHO-GFP; ** P< 0.05 versus PODXL-GFP.  
 
FIGURE 3. Activity of Rac1 and Cdc42 in CHO cells expressing PODXL-GFP or 
its deletion mutants. A) Representative Western blot of active (A) and total (T) 
Rac1. B) Average values of active (upper) and total (lower) Rac1 of 6 
experiments. C) Representative Western blot of active (A) and total (T) Cdc42. 
D) Average values of active (upper) and total (lower) Cdc42 of 6 experiments. 
By paired t test: *P<0.05 versus CHO-GFP; **P<0.05 versus PODXL-GFP. 
 
FIGURE 4. Suppression of rac1 gene diminished the effect of PODXL in 
enhancing adhesion and migration of CHO cells. A) Representative Western 
! ")!
blot analysis of Rac1 expression at the indicated times after iRNA transfection. 
B) Left panel: quantification of the results of three different experiments 
performed as in A). Right panel: Adhesion of PODXL-GFP cells at different 
times after iRNA addition. The experiment was performed as described in Fig. 
2. The results are mean values of three different experiments and the vertical 
bars the standard error of the mean. C) Time course of adhesion (left panel) 
and migration (right panel) capacities of CHO cells expressing GFP or PODXL-
GFP after 24-h incubation in the presence or in the absence of iRNA. 





